Analysis of Novavax Shares Novavax Shares: Bet on the Protein Vaccine?

Analysis of Novavax Shares Novavax Shares: Bet on the Protein Vaccine?

Analysis of Novavax Shares Novavax Shares: Bet on the Protein Vaccine?

The pandemic is coming back with full severity. As queues re-emerge in front of vaccination centers, some people remain skeptical of MRNA and vector vaccines. Vaccines based on established technology could possibly convince them – such as the protein-based vaccine from. The share benefits from this hope, having gained more than 25-fold since the end of February 2020.

There was a further boost to the course on Monday: The European Medicines Agency (EMA) cleared the way for the approval of the corona vaccine. The responsible commission of experts issued the recommendation after an extraordinary meeting. The experts had already evaluated studies on the effects and risks in the long-running test procedure. After a detailed assessment, the responsible committee came to the conclusion that “the EU criteria for effectiveness, safety and quality are met,” said the EMA. Now the EU Commission has to give its approval. But that is a matter of form.